Literature DB >> 23403242

Histopathological findings in livers of patients with urea cycle disorders.

Joy Yaplito-Lee1, Chung-Wo Chow, Avihu Boneh.   

Abstract

BACKGROUND: Urea cycle disorders (UCD) are caused by genetic defects in enzymes that constitute the hepatic ammonia detoxification pathway. Patients may present with variable clinical manifestations and with hyperammonaemia. Liver abnormalities have been associated with UCD, but only a few reports on the histopathological findings in the liver of UCD patients have been published.
METHODS: We conducted a retrospective review of liver biopsies, ex-planted livers and livers at post-mortem of patients with UCD. A single pathologist reviewed all specimens.
RESULTS: There were 18 liver samples from 13 patients with confirmed UCD: four ex-planted livers from patients with Ornithine Transcarbamylase (OTC) (n=3) and Carbamoyl Phosphate Synthetase 1 (CPS 1) (n=1) deficiencies, eight post-mortem samples from patients with CPS 1 (n=2), OTC (n=4), Argininosuccinate Synthetase (ASS) (n=1) and Argininosuccinate Lyase (ASL) (n=1) deficiencies, and six liver biopsies, three of which came from one patient with ASL deficiency. The other three liver biopsies were from patients who subsequently received liver transplantation. Histopathological findings in samples from neonates were non-specific. Samples from three late onset OTC deficient and one ASL deficient patients showed thin fibrous septa with portal to portal bridging fibrosis and focal marked enlargement and pallor of the hepatocytes due to accumulation of glycogen particles, resembling glycogenosis and resulting in a prominent nodular pattern. Serial liver biopsies in four UCD patients with interval between samples ranging from 1 year 2 months to 17 years showed progression in fibrosis in one OTC and one ASL deficient patients. Moderate fatty changes to no progression in liver disease were noted in the two patients (OTC=1 and CPS=1). A variety of non-specific features such as fatty change, mild inflammation, cholestasis and focal necrosis were seen in the other UCD patients.
CONCLUSIONS: Histopathological changes in livers from neonates with UCD are non-specific. Older patients with UCD seem to show variable hepatic fibrosis compared to those who died early. Some of these patients also show focal and superficial resemblance to a glycogen storage disorder and cirrhosis. However, progression of these changes seems to be slow. To clarify the long term consequence of these changes, more extensive periods of follow up in a larger population series is needed. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403242     DOI: 10.1016/j.ymgme.2013.01.006

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  15 in total

1.  The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype.

Authors:  Stefan Kölker; Vassili Valayannopoulos; Alberto B Burlina; Jolanta Sykut-Cegielska; Frits A Wijburg; Elisa Leão Teles; Jiri Zeman; Carlo Dionisi-Vici; Ivo Barić; Daniela Karall; Jean-Baptiste Arnoux; Paula Avram; Matthias R Baumgartner; Javier Blasco-Alonso; S P Nikolas Boy; Marlene Bøgehus Rasmussen; Peter Burgard; Brigitte Chabrol; Anupam Chakrapani; Kimberly Chapman; Elisenda Cortès I Saladelafont; Maria L Couce; Linda de Meirleir; Dries Dobbelaere; Francesca Furlan; Florian Gleich; Maria Julieta González; Wanda Gradowska; Stephanie Grünewald; Tomas Honzik; Friederike Hörster; Hariklea Ioannou; Anil Jalan; Johannes Häberle; Gisela Haege; Eveline Langereis; Pascale de Lonlay; Diego Martinelli; Shirou Matsumoto; Chris Mühlhausen; Elaine Murphy; Hélène Ogier de Baulny; Carlos Ortez; Consuelo C Pedrón; Guillem Pintos-Morell; Luis Pena-Quintana; Danijela Petković Ramadža; Esmeralda Rodrigues; Sabine Scholl-Bürgi; Etienne Sokal; Marshall L Summar; Nicholas Thompson; Roshni Vara; Inmaculada Vives Pinera; John H Walter; Monique Williams; Allan M Lund; Angeles Garcia-Cazorla; Angeles Garcia Cazorla
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

2.  Acute liver dysfunction with delayed peak of serum aminotransferase levels as a presentation of ornithine transcarbamylase deficiency in females.

Authors:  Kathryn Clarkston; Joy Lee; Sarah Donoghue; Heidi Peters; Hernan Eiroa; Amit A Shah; Kathleen Loomes; Jessica Wen; Mark Oliver; Winita Hardikar; Carlos E Prada; Akihiro Asai
Journal:  Am J Med Genet A       Date:  2020-12-24       Impact factor: 2.802

3.  Variable X-chromosome inactivation and enlargement of pericentral glutamine synthetase zones in the liver of heterozygous females with OTC deficiency.

Authors:  Dita Musalkova; Eva Sticova; Martin Reboun; Jitka Sokolova; Jakub Krijt; Jitka Honzikova; Jiri Gurka; Magdalena Neroldova; Tomas Honzik; Jiri Zeman; Milan Jirsa; Lenka Dvorakova; Martin Hrebicek
Journal:  Virchows Arch       Date:  2018-04-06       Impact factor: 4.064

4.  Dose-, treatment- and time-dependent toxicity of superparamagnetic iron oxide nanoparticles on primary rat hepatocytes.

Authors:  Kurtulus Gokduman; Furkan Bestepe; Lei Li; Martin L Yarmush; O Berk Usta
Journal:  Nanomedicine (Lond)       Date:  2018-06       Impact factor: 5.307

5.  Significant hepatic involvement in patients with ornithine transcarbamylase deficiency.

Authors:  Renata C Gallagher; Christina Lam; Derek Wong; Stephen Cederbaum; Ronald J Sokol
Journal:  J Pediatr       Date:  2014-01-30       Impact factor: 4.406

6.  Chronic liver disease and impaired hepatic glycogen metabolism in argininosuccinate lyase deficiency.

Authors:  Lindsay C Burrage; Simran Madan; Xiaohui Li; Saima Ali; Mahmoud Mohammad; Bridget M Stroup; Ming-Ming Jiang; Racel Cela; Terry Bertin; Zixue Jin; Jian Dai; Danielle Guffey; Milton Finegold; Sandesh Nagamani; Charles G Minard; Juan Marini; Prakash Masand; Deborah Schady; Benjamin L Shneider; Daniel H Leung; Deeksha Bali; Brendan Lee
Journal:  JCI Insight       Date:  2020-02-27

7.  Hepatic Encephalopathy Is Not Always due to Liver Cirrhosis.

Authors:  Miriam Eva Ecker; Maria Paparoupa; Bernd Sostmann; Karin Weissenborn; Frank Schuppert
Journal:  Case Rep Gastroenterol       Date:  2022-05-20

8.  Novel two-step derivation method for the synchronous analysis of inherited metabolic disorders using urine.

Authors:  Xiao-Qi Sheng; Yi-Chao Wang
Journal:  Exp Ther Med       Date:  2017-03-02       Impact factor: 2.447

9.  AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.

Authors:  Lili Wang; Peter Bell; Hiroki Morizono; Zhenning He; Elena Pumbo; Hongwei Yu; John White; Mark L Batshaw; James M Wilson
Journal:  Mol Genet Metab       Date:  2017-03-02       Impact factor: 4.797

10.  Biomarkers for liver disease in urea cycle disorders.

Authors:  Sandesh C S Nagamani; Saima Ali; Rima Izem; Deborah Schady; Prakash Masand; Benjamin L Shneider; Daniel H Leung; Lindsay C Burrage
Journal:  Mol Genet Metab       Date:  2021-04-08       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.